View more job listings or post a job
University of California, Davis TOXICOLOGY GROUP LEADER (LABORATORY RESCHEARCH SUPERVISOR 2)                    
Xencor Scientist, Immuno-Oncology
Xencor Research Associate 3, Immuno-Oncology
Genentech Senior Scientist, Small Molecule Analytical Chemistry
Horizon Therapeutics Director, Nonclinical Safety (Toxicology) R0004281
Roivant Sciences Director, Translational Sciences and Immunology
Horizon Therapeutics Senior Clinical Pharmacologist
Post a job


[Free Online Symposium]Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)

Speakers: Juan Jaen, Arcus Bio; Rena Bahjat, Apexigen; Lelia Delamarre, Genentech; Alex Franzusoff, PACT Pharma; Nadine Defranoux, Parker Institute; Terri McClanahan, Merck; Mary J. Janatpour, Dynavax; Hong Jin, AstraZeneca; Michelle Monje Deisseroth, Stanford; Ana Krtolica, Omniox; Wei Lin, Nektar
Organizers: Shichang Miao, Joseph Carlino, Toby Freedman, Donald McCarthy, Betty Chang, Wenfeng Xu, Snow Ge
Date: 2020-07-28- 7/29/2020
Time: 8:30-12:30 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; Students & Unemployed: $35; Major Sponsor's Rep (incl lunch): $0
Location: Online via Zoom
Major Sponsor: (3)Applied BioMath, LLC; KCAS Bioanalytical & Biomarker Services; PerkinElmer;(Sponsorship - Reception still open)
Vendor show vendors registered to date: (25)ACROBiosystems; Analytical Lab Group; Applied StemCell; Aragen Bioscience; Benchling; BioDuro; Celerion; cgenetool; Charles River Labs; CMIC, Inc.; Correlia Biosystems; Cytobank; Intertek; Lonza; Novogene Corporation; PeproTech Inc; PHC former Panasonic Healthcare; Promega corporation; Q2 Solutions; Qognit Inc; R&D Systems; SEKISUI XenoTech; Thermo Fisher Scientific; Viracor Eurofins; WuXi Apptec
Registration deadline:2021-07-27  (it will close sooner if the seating cap is reached)

About the Topic

The last few years has seen major advancements in cancer treatment through immunotherapy. This symposium aims to provide a comprehensive overview of the emerging concepts in cancer immunotherapy from the latest biologic insights in academia and the latest clinical data for approved and investigational immuno-oncology agents from key biotech and pharmaceutical companies. We will discuss the latest partnership trends and business development efforts in this rapidly evolving landscape. 


8:45-9:00           Welcome and Overview (Shichang Miao, PhD, President, PBSS; Joseph Carlino, PhD, President, BioScience Forum)

9:00-9:40           1. a. Immuno-Oncology Overview; b. Enhancing Anti-Tumor Immunity by Inhibition of the Adenosine Axis (Juan Jaen, PhD, President, Arcus Biosciences)

9:40-10:10         2. Genomic Determinants of Response to Pembrolizumab: Impact on Combination Strategies for Cancer Immunotherapy (Terri McClanahan, PhD, Exec Dir Profiling and Expression, Translational Medicine, Merck)

10:10-10:40       3. Neoantigen-Specific Immunotherapy (Lelia Delamarre, Genentech)

10:40-10:50       Major Sponsor Presentation (KCAS Bioanalytical)

10:50-11:10       Break

11:10-11:40       4. Personalized T Cell Immunity Against Cancer – Accelerating Evolution for Clinical Benefit (Alex Franzusoff, PhD, CEO, PACT Pharma)

11:40-12:10       5. Predicting Neoepitopes: The TESLA Consortium (Nadine Defranoux, PhD, Research Project Manager, Parker Institute for Cancer Immunotherapy)

12:10-13:00       Lunch (sponsored by PerkinElmer)

13:00-13:30       6. Targeting the Co-stimulatory Molecule CD40 for Cancer Immunotherapy with APX005M Agonist Antibody (Rena Bahjat, PhD, VP Discovery Research, Apexigen)

13:30-14:00       7. Harnessing Innate Immunity to Improve Efficacy of Checkpoint Blockade (Mary J. Janatpour, PhD, VP Oncology Research, Dynavax)

14:00-14:30       8. Oncolytic Newcastle Disease Virus for Cancer Therapy (Hong Jin, PhD, Senior Director/Fellow, AstraZeneca)

14:30-14:40       Major Sponsor Presentation (Applied Biomath)

14:40-15:00       Break

15:00-15:30       9. CAR-T Cell Therapy for Glioma (Michelle Monje Deisseroth, MD, PhD, Associate Professor, Stanford School of Medicine)

15:30-16:00       10. Taming of the Tumor Microenvironment: OMX-302 Reduces Hypoxia-induced Immunosuppression (Ana Krtolica, VP, Research & Development, Omniox Inc.)

16:00-16:30       11. NKTR-214 (Pegylated IL-2) (Wei Lin, MD, SVP Clinical Development, Nektar)

16:30-17:00       Panel Discussion (All Speakers)

17:00-18:00       Reception (All)


About the Speakers

Juan Jaen, Ph.D. – President and Co-founder of Arcus Biosciences

Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry. From 1983 to 1996, Dr. Jaen held various scientific leadership positions at Parke-Davis/Warner-Lambert. Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Dr. Jaen has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.

Terri McClanahan, Ph.D. - Executive Director, Profiling & Expression Group, Translational Medicine at Merck Research Laboratories

Dr. McClanahan is currently the Executive Director of the Profiling & Expression group in Biologics Discovery at Merck Research Laboratories. Her group combines multiple molecular, cellular and tissue-based approaches to interrogate disease mechanisms, working closely with discovery biologists and drug development teams to provide mechanistic data, disease association and biomarkers of drug response. She oversees and integrates the work of several key areas utilizing multiple tissue-based methodologies including histopathology, flow cytometry, cell sorting and molecular profiling, to support projects spanning from the earliest novel discovery projects to IND-enabling mechanistic studies, tissue, cell type and disease tissue expression profiling, and translational biomarker discovery, with a specific emphasis on immune regulation and immune-oncology. Dr. McClanahan and her group provided important molecular insights in the discovery and characterization of Th17 cells, the mechanism of action of IL-23/IL-23R, IL-17 and additional targets involved in autoimmune diseases, and provided key data to progress these molecules towards development. Her group has contributed to the molecular understanding of immune regulation in anti-tumor responses to anti-PD-1 and additional immunomodulatory pathways, including biomarkers associated with response to immune therapy in oncology. During her career, she has contributed to over 95 published scientific articles, contributed to IND filings for anti-IL-10, anti-IL-17, anti-IL-23, anti-TSLP, anti-PD-1, anti-GITR, anti-LAG3 and is a co-inventor on numerous patents. She received her Ph.D. in Biological Chemistry from University of California, Los Angeles, and conducted postdoctoral research fellowships at Northwestern University in Evanston, IL and at DNAX Research Institute in Palo Alto, CA.

Lelia Delamarre, Ph.D. – Senior Scientist in Cancer Immunology at Genentech

Dr Delamarre is senior scientist in cancer immunology at Genentech. She joined Genentech in 2007 after her postdoctoral training at Yale University where she studied the cellular mechanisms underlying the unique capacity of dendritic cells to capture and present antigens for T cell priming. At Genentech in the Cancer Immunology Department, Dr Delamarre has been pursuing her research interests with the goal of developing novel approaches to expand effective T cell responses to cancer through priming. She has a PhD in Virology from the University of Paris.

Alex Franzusoff, Ph.D. – Chief Executive Officer at PACT Pharma

Dr. Franzusoff joined PACT Pharma in January 2017. Previously, he was consulting for several private and public biotech/pharma companies in the I-O space, in addition to his role as founder and CEO of Krypton Immuno-oncology. At Bavarian Nordic, he worked at the forefront of the electrified I-O space as SVP R&D, which resulted in the $1B deal with BMS for Prostvac, its Ph3 cancer immunotherapy product. He had returned to California for that role, from Boston, after serving as Chief Executive Officer and Board Director for AZTherapies, developing Alzheimer’s therapies based on re-purposing previously approved drugs via the 505(b)2 pathway for Phase 3 studies. He previously led the venture-backed Permeon Biologics as President and a member of the board of directors. Dr. Franzusoff’s career in the biotechnology industry was launched with the co-founding of the biotech GlobeImmune, Inc., where he served as Vice President of Research & Development for immunotherapy against cancer & infectious diseases. Dr. Franzusoff trained as a Postdoctoral Fellow with the Nobel Laureate, Dr. Randy Schekman, at the University of California, Berkeley after earning his Ph.D. in Biochemistry at SUNY at Stony Brook. He was a tenured Associate Professor at the University of Colorado, School of Medicine until 2004.

Rena Bahjat, Ph.D. – Vice President of Discovery Research at Apexigen

Dr. Bahjat joined Apexigen in May of 2018 as Vice President, Discovery Research. Prior to joining Apexigen, Dr. Bahjat served as Senior Director of In vivo Studies for Bristol-Myers Squibb Biologics Discovery California site where she was responsible for overseeing Biologics Discovery Pharmacology and In vivo Antibody Discovery operations for the company. Prior to joining BMS, Dr. Bahjat was an Assistant Professor at Oregon Health & Sciences University where she conducted NIH-funded basic and translational research and facilitated preclinical development of innate agonist therapeutics for clinical use. Prior to that, Dr. Bahjat served as Associate Director of Pharmacology at Rigel Pharmaceuticals where she contributed to the preclinical development of kinase inhibitors for cancer, allergy, and autoimmune diseases, including the recently approved Tavalisse™ for Chronic Immune Thrombocytopenia (ITP). Dr. Bahjat also held positions at Oncovir (Washington, DC), Nuvelo now Arca Biopharma (Westminster, CO), Corgentech-AlgoRX (South San Francisco, CA) and Nereus Pharmaceuticals (San Diego, CA). Dr. Bahjat is an immunologist and pharmacologist specializing in inflammation biology and in vivo disease modeling in rodents and nonhuman primates. Dr. Bahjat has nearly 20 years of experience encompassing target discovery and preclinical and clinical development of biologics and small molecules for cancer, as well as autoimmune and inflammatory diseases. Dr. Bahjat studied Biomedical Sciences and Immunology at the University of Florida College of Medicine in Gainesville, Florida where she earned her Doctorate in Immunology.

Mary J. Janatpour, Ph.D. – Vice President of Oncology Research at Dynavax Technologies

Dr. Janatpour has over 20 years of industry research experience, the bulk of which has been in oncology. For the first 15 years of her cancer research career, she helped build oncology pipelines, focused on novel targets, at companies such as Chiron Corporation, Schering-Plough Biopharma and Novartis. Just prior to joining Dynavax in 2016, she worked as a consultant for several companies, including two start-up immuno-oncology companies with novel platforms. At Dynavax, Dr. Janatpour led the clinical DV281 lung cancer program through Phase 1a and the primary focus of her laboratory is to identify rational combinations with TLR9 agonists, as well as to expand on strategies to target TLR agonists to tumors. Dr. Janatpour received a Bachelor’s degree in Molecular Biology from the University of California, Berkeley and a Ph.D. in Biomedical Scienceth from the University of California, San Francisco. She did her post-doctoral training in Immunology at the DNAX Research Institute in Palo Alto, CA.

Hong Jin, Ph.D. – Senior Director/Fellow at MedImmune

Currently, Dr. Jin is a Sr. Director/Fellow managing various Virology and TS programs including cancer vaccine, oncolytic virus for cancer therapy and anti-RSV mAb TS studies (phase II) at MedImmune. Previously as project leader of influenza vaccine programs in research and development of seasonal and pandemic influenza vaccines by reverse genetics and respiratory syncytial virus vaccine development by reverse genetics. Dr. Jin did her post-doctoral studies in influenza virus assembly at Northwestern University and completed her Ph.D. in Virology at Glasgow University.

Michelle Monje Deisseroth, MD, Ph.D. - Associate Professor, Stanford University School of Medicine

Michelle Monje, MD, PhD joined the faculty at Stanford University in 2011 as an Assistant Professor of Neurology and Neuro-Oncology. Following her undergraduate degree in biology at Vassar College, Dr. Monje received her MD and PhD in Neuroscience from Stanford University. She then completed neurology residency at the Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School program. She subsequently returned to Stanford for a clinical fellowship in pediatric neuro-oncology and a postdoctoral fellowship. The scope of her research program encompasses the molecular determinants of neural precursor cell fate, neuronal-glial interactions, and the role of neural precursor cells in oncogenesis and repair mechanisms. As a practicing neurologist and neuro-oncologist, Dr Monje is dedicated to understanding the neurodevelopmental origins of pediatric brain tumors and the neurological consequences of cancer treatment.

Ana Krtolica, PhD - VP Research & Development, Omniox Inc.

Wei Lin, MD – Senior Vice President of Clinical Development at Nektar Therapeutics

Dr. Wei Lin, M.D., is the Senior Vice President of Clinical Development and Head of Nektar’s Oncology Programs. Dr. Lin has nearly a decade of experience in oncology, with expertise in lung and head and neck cancers. Prior to joining Nektar, Dr. Lin served as the Global Development Leader for cancer immunotherapy in lung and head and neck cancer at Genentech from 2011 to 2018. During his seven years at Genentech, he held several senior leadership positions of increasing responsibility including Global Clinical Leader of Cancer Immunotherapy in lung and head and neck cancer, where he led a team of 20 medical directors and clinical scientists and directed clinical development strategy for cancer immunotherapy in lung cancer and executed registration trials in lung cancer and head and neck cancer including the successful readouts of five Phase 3 trials in first-line lung cancer and regulatory filing of three of these trials. In addition, he also served as the Site Head for Oncology Development in Roche Asia Pacific and oversaw the regulatory approval of three oncology products in China. Prior to Genentech, Dr. Lin was a faculty member at M.D. Anderson Cancer Center in Houston in the Department of Thoracic/Head and Neck Medical Oncology. Dr. Lin has extensive clinical research experience and has been published in more than 15 peer-reviewed journals. Dr. Lin received a B.A. in physics from Haverford College and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital in Boston and a fellowship in medical oncology at the University of Texas M.D. Anderson Cancer Center.

2022-12-07, [Free Online Symposium] Gene Therapy: Discovery, Development and Regulatory Perspectives
2022-12-15, [Free Online Symposium] Success Stories and Lessons Learned from Recent FDA Approvals: INQOVI (decitabine+cedazuridine) by Astex - Otsuka for the treatment of myelodysplastic syndromes (MDS)
2023-02-06, [Free Online Symposium] Promising Biotech Startups
2023-02-08, [Free Online Workshop] New Product Launch: What Does it Take to Bring a New Product to Market?
©Pharmaceutical & BioScience Society, International; Last Modified: 12/3/2022; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Programmable Drug Delivery Evaluate drug efficacy in animal models in a clinically relevant manner with a Programmable Refillable and implantable pump. 3Rs and group housed.
Hypha Discovery Synthesis, purification & NMR characterization of phase 1 and 2 drug metabolites at mg-g scale with COAs. New gut metabolites service.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Programmable Drug Delivery PK/PD models and the limitations of traditional dosing methods. Methods & benefits of implantable microinfusion pumps in both rats & mice.
Submit a Text Ad